Zacks Investment Research upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a sell rating to a hold rating in a research note released on Tuesday morning.
According to Zacks, “Alnylam reported positive data from the ATLAS study which led to regulatory filings for its late-stage pipeline candidate patisiran and an action date of Aug 11, 2018 as set by the FDA. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020. Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company. Stiff competition remains a threat as well. Estimates have remained stable ahead of the Q1 earnings results.”
Other analysts have also recently issued reports about the company. B. Riley reduced their price target on Alnylam Pharmaceuticals from $205.00 to $200.00 and set a buy rating for the company in a report on Friday, February 16th. BidaskClub raised Alnylam Pharmaceuticals from a hold rating to a buy rating in a report on Wednesday, March 14th. Chardan Capital reaffirmed a buy rating on shares of Alnylam Pharmaceuticals in a report on Friday, January 19th. Piper Jaffray reaffirmed a buy rating and set a $182.00 price objective on shares of Alnylam Pharmaceuticals in a report on Sunday, January 7th. Finally, Credit Suisse Group set a $151.00 price objective on Alnylam Pharmaceuticals and gave the stock a buy rating in a report on Friday, February 9th. Four equities research analysts have rated the stock with a sell rating, four have issued a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $134.15.
ALNY opened at $97.48 on Tuesday. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $9,786.75, a PE ratio of -17.99 and a beta of 2.68. Alnylam Pharmaceuticals has a 12 month low of $49.19 and a 12 month high of $153.99.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing the consensus estimate of ($1.38) by ($0.10). The business had revenue of $37.90 million during the quarter, compared to analyst estimates of $19.31 million. Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 41.08%. The firm’s quarterly revenue was up 116.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.32) earnings per share. research analysts forecast that Alnylam Pharmaceuticals will post -7.02 EPS for the current fiscal year.
In other news, insider Akshay Vaishnaw sold 88,554 shares of the business’s stock in a transaction on Wednesday, March 14th. The stock was sold at an average price of $143.10, for a total value of $12,672,077.40. Following the completion of the transaction, the insider now directly owns 55,856 shares of the company’s stock, valued at $7,992,993.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Yvonne Greenstreet sold 7,221 shares of the business’s stock in a transaction on Monday, March 26th. The stock was sold at an average price of $136.54, for a total value of $985,955.34. Following the completion of the transaction, the chief operating officer now directly owns 7,221 shares of the company’s stock, valued at $985,955.34. The disclosure for this sale can be found here. Over the last three months, insiders sold 198,620 shares of company stock valued at $28,404,143. Insiders own 4.30% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 16.4% in the fourth quarter. BlackRock Inc. now owns 7,115,063 shares of the biopharmaceutical company’s stock worth $903,969,000 after acquiring an additional 1,003,366 shares during the last quarter. UBS Asset Management Americas Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 2.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,394,213 shares of the biopharmaceutical company’s stock worth $177,135,000 after acquiring an additional 29,816 shares during the last quarter. Gilder Gagnon Howe & Co. LLC raised its holdings in shares of Alnylam Pharmaceuticals by 8.6% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 1,217,367 shares of the biopharmaceutical company’s stock worth $154,666,000 after acquiring an additional 96,812 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 13.4% in the fourth quarter. Geode Capital Management LLC now owns 747,646 shares of the biopharmaceutical company’s stock worth $94,929,000 after acquiring an additional 88,119 shares during the last quarter. Finally, Bridger Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 30.3% in the fourth quarter. Bridger Management LLC now owns 500,219 shares of the biopharmaceutical company’s stock worth $63,553,000 after acquiring an additional 116,286 shares during the last quarter. 92.00% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/21/alnylam-pharmaceuticals-alny-upgraded-to-hold-by-zacks-investment-research.html.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.